Biologic drugs in Gastroenterology

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for any medical condition, and if possible, for Ulcerative Colitis, with the following biologic drugs: Adalimumab – Humira, Adalimumab Biosimilar, Filgotinib, Golimumab, Infliximab – Remicade, Infliximab Biosimilar, Ozanimod, Tofacitinib, Ustekinumab, Vedolizumab

Please see below data held for Gastroenterology patients.  The Trust can provide the number of patients, but unable to provide the indication that the drug was prescribed for as this is not recorded against pharmacy data.  Therefore we are unable to advise how many patients were issued drugs for ulcerative colitis.  If the drug is not listed, it is because it has not been issued.

HOMECARE ADALIMUMAB (AMGEVITA) 40 mg in 0.8ml Pre-filled Pen
Number of patients: <5

HOMECARE ADALIMUMAB (HUMIRA) 40 mg in 0.4ml Pre-filled Pen
Number of patients: 12

HOMECARE ADALIMUMAB (IMRALDI) 40 mg in 0.8ml Pre-filled Pen
Number of patients: 105

HOMECARE GOLIMUMAB (SIMPONI) 100 mg Pre-filled Pen
Number of patients: <5

HOMECARE GOLIMUMAB (SIMPONI) 50 mg Pre-filled Pen
Number of patients: <5

HOMECARE INFLIXIMAB (REMSIMA) 120 mg Pre-filled Pen
Number of patients: 7

HOMECARE TOFACITINIB (XELJANZ) 5 mg Tablets
Number of patients: <5

HOMECARE USTEKINUMAB (STELARA) 90 mg in 1ml Pre-filled Syringe
Number of patients: 12

HOMECARE VEDOLIZUMAB (ENTYVIO SC) Pre-filled Pen 108 mg in 0.68ml for SUBCUTANEOUS Injection
Number of patients: 10

inFLIXimab (INFLECTRA) 100 mg Intravenous Infusion
Number of patients: <5

inFLIXimab (REMICADE) 100 mg Intravenous Infusion
Number of patients: <5

inFLIXimab (REMSIMA) 100 mg Intravenous Infusion
Number of patients: 67

USTEKINUMAB 130 mg Solution for Infusion Vial
Number of patients: 5

VEDOLIZUMAB 300 mg Powder for Solution Infusion
Number of patients: 34